Forbes Magazine Names CSL Limited Among Top 50 Employers in the World

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth

KING OF PRUSSIA, Pa. – March 20, 2018 – Forbes has named global biotechnology leader CSL Limited among the world’s Top 50 employers, landing at no. 42 in the business media’s annual Global 2000 survey.

The Forbes list was compiled by Statista, which surveyed 30,000 workers. The survey asked whether they like where they work and if they would recommend the company to family and friends.

CSL is comprised of two businesses: CSL Behring, a recognized global leader in providing life-saving biotherapies for people stricken with rare and serious diseases and accounts for more than 90 percent of CSL’s annual revenue, and Seqirus, the world’s second largest influenza vaccines provider. According to the Statista survey, CSL employees:

  • are inspired by CSL’s patient focus
  • believe CSL focuses on innovation more than peer organizations
  • feel CSL is more conscious of its impact to the world
  • are excited to be part of a growing company
  • are particularly proud of CSL values

“CSL is a passionate and reputable organization known for keeping its promises – to patients, communities and employees. It’s the very essence of who we are,” said EVP & Chief Human Resources Officer Elizabeth Walker. “CSL’s 20,000 employees enjoy promising futures.  We invest in our people so they may fulfil their career goals and are inspired by a purpose-driven company with a values-based culture. Our environment is collaborative, global and dynamic, which fosters innovation and drives results for shareholders. All of this is done while our people are saving lives and protecting the health of people around the world every day.”

For Forbes’ complete annual global best employers rankings, click: www.forbes.com/world-best-employers/list

About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

 

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, and delivers its life-saving therapies to people in more than 60 countries. For more information visit www.CSLBehring.com and follow us on www.Twitter.com/CSLBehring.

###


Media Contact
Chris Florentz
Office: 610-878-4316
Mobile: 484-238-8509
Email:
christopher.florentz@cslbehring.com